Expert View: Wearable Technology And The FDA Adoption Curve
This article was originally published in Scrip
Executive Summary
The US FDA recently announced that it will carefully consider the value of mobile technology in clinical research. By and large, the process of testing and approving new drugs and therapies has remained unchanged for the past 50 years. Today, data collected in everyday devices like smartphones and wearable fitness trackers could make clinical trials safer for patients and provide meaningful data to the FDA, write Barbara Elashoff and Glen de Vries of Medidata Solutions.
You may also be interested in...
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.